Clinical Trial Listing

2009.096.A - Leukemia and the effects of Lenalidomide as Maintenance Therapy (The CONTINUUM Trial)

The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug.

2010.064.B - Leukemia and the effects of Pentostatin, Cyclophosphamide, and Rituximab followed by Alemtuzumab

This phase II trial is studying how well pentostatin, cyclophosphamide, rituximab, and alemtuzumab work in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia.

2011.103.B - Studying First-Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-World Setting (SIMPLICITY)

The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.

2011.151.C - Acute Myeloid Leukemia and the effects of Vosaroxin and Cytarabine

This study will compare the overall survival (OS) between treatment groups of patients treated with vosaroxin and cytarabine versus patients treated with placebo and cytarabine.

2012.026.N - Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

AALL08B1- Classification of Newly Diagnosed Acute Lymphoblastic Leukemia Rajasekharan Warrier, M.D. 2012.026.N Open to new patients Not Applicable This research study is developing a risk-based classification system for patients with newly diagnosed acute lymphoblastic leukemia. DISEASE CHARACTERISTICS:

2012.086.N - Lymphoblastic Leukemia and the effects of Risk-Adapted Chemotherapy

This partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia.